Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that Alan H. Auerbach, the CEO and Founder, will present at the H.C. Wainwright Global Life Sciences Conference virtually on March 9-10, 2021. The presentation will be available on demand starting at 7:00 a.m. EST on March 9 and will remain accessible for 30 days on Puma's website.

Puma specializes in developing and commercializing innovative cancer care products, including NERLYNX® (neratinib), approved by the FDA for treating breast cancer.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright Global Life Sciences Conference, which will be held virtually on March 9-10, 2021. The presentation will be available on demand beginning at 7:00 a.m. EST on March 9, 2021.

The virtual presentation will be available for 30 days on the Company’s website at www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005961/en/

FAQ

What is Puma Biotechnology's presentation at the H.C. Wainwright Conference?

Puma Biotechnology will present an overview by CEO Alan H. Auerbach at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will Puma Biotechnology's presentation be available?

The presentation will be available on demand starting at 7:00 a.m. EST on March 9, 2021.

How long will the presentation from Puma Biotechnology be accessible?

The presentation will remain accessible for 30 days on Puma's website.

What products does Puma Biotechnology focus on?

Puma Biotechnology focuses on developing and commercializing innovative cancer care products, including NERLYNX® (neratinib).

What is NERLYNX® and its significance?

NERLYNX® is an FDA-approved oral treatment for early stage and advanced HER2-positive breast cancer, enhancing cancer care options.